Skip to main content
. 2014 Jan 6;123(10):1455–1460. doi: 10.1182/blood-2013-09-453092

Table 2.

Selected BCR-signaling antagonists in clinical development for CLL indications

Target Agent Manufacturer Study phase
BTK Ibrutinib (PCI-32765) Pharmacyclics/Janssen 3
CC-292 (AVL-292) Celgene 1b/2
GDC-0834 Genentech 1
ACP-196 Acerta 1
ONO-WG-307 Ono 1
PI3Kδ Idelalisib (GS-1101, CAL-101) Gilead Sciences 3
GS-9820 Gilead Sciences 2
AMG-319 Amgen 1
TGR-1202 TG Therapeutics 1
PI3Kδ/γ IPI-145 Infinity 3
Syk GS-9973 Gilead Sciences 2